Leronlimab
Monoclonal antibody against CCR5, for prevention of fusion of HIV with CCR5+ cells
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
Nº Q7120418 ★★
Uncommon · Knowledge
Leronlimab
Monoclonal antibody against CCR5, for prevention of fusion of HIV with CCR5+ cells
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection.
From Wikipedia
Leronlimab (codenamed PRO 140) is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of triple negative breast cancer and HIV infection. The United States Food and Drug Administration has designated PRO 140 for fast-track approval. It was investigated as a treatment for COVID-19 but found to be ineffective for that purpose.
Text: Wikipédia, CC BY-SA 4.0. ·
Related cards
-
Belimumab
Pharmaceutical drug
Nº Q1996249 ★
Not listed
-
Adalimumab
Pharmaceutical drug
Nº Q348260 ★★★
Not listed
-
Obinutuzumab
Pharmaceutical drug
Nº Q389496 ★
Not listed
-
Cetuximab
Pharmaceutical drug
Nº Q420296 ★
Not listed
-
S
Sarilumab
Chemical compound
Nº Q7424081 ★
Not listed
-
A
Abatacept
Pharmaceutical drug
Nº Q2697833 ★
Not listed